Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T celllymphomas
Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T celllymphomas
批准号:
10071043
负责人:
Carlos A. Murga-Zamalloa
金额:
$8.25万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-01-01 至 2021-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
T-cell lymphomas display shorter relapse intervals and poor overall survival. Targeted therapies for T-cell
lymphomas are lacking, and there is no established standard of care for patients at relapse. The limited
information on the specific molecular signals that are activated in T-cell lymphomas hampers the development
of effective therapies. Emergent research has demonstrated that aberrant activation of proteins involved in
actin organization is critical for cancer metastasis and tumor growth. The candidate preliminary studies
demonstrate that a large network of actin organizing proteins is activated during the development of T-cell
lymphoma. Also, the major actin regulatory protein Wiskott-Aldrich syndrome protein (WASp) increases the
dissemination and growth of a subtype of T-cell lymphoma, anaplastic large cell lymphoma (ALCL). These
preliminary findings are very exciting, as identified a major actin regulatory protein as key determinant for
lymphoma development. However, whether WASp also plays a role in lymphoma development in more
common and aggressive types of T-cell lymphomas needs to be determined. The candidate novel preliminary
findings demonstrate that WASp is expressed and activated in the most common type of T-cell lymphoma in
the United States, peripheral T- cell lymphoma, non-otherwise specified (PTCL-NOS). In addition, WASp
expression decreases the sensitivity of primary T-cell lymphoma cells to available chemotherapeutics,
suggesting a role of WASp in chemotherapy resistance. Moreover, WASp can activate downstream proteins
known to increase tumor proliferation and dissemination. Among these proteins, activation of lymphocyte
specific protein 1 (LSP1) and extracellular signal-regulated kinase (ERK) in T-cell lymphomas has been
validated. Importantly, ERK pathway can be inhibited with drugs that are currently in clinical trials for other
types of cancer. The central hypothesis is that WASp and its downstream signals (ERK and LSP1) are
therapeutic targets for patients with a diagnosis of T-cell lymphoma. In this proposal, I will evaluate 1) the role
of WASp and its downstream signals (ERK and LSP1) during lymphoma growth, 2) the role of WASp
dependent actin re-organization during T-cell lymphoma dissemination, 3) the signaling pathways that mediate
WASp-dependent chemotherapy resistance, and 4) the oncogenic role of WASp in-vivo using a mice model of
T-cell lymphoma with knock-down expression of WASp. The candidate long term career goal is to develop as a
successful independent physician-scientist with a research focus in the pathobiology of T-cell lymphomas. The
candidate career development plan is structured in three main components to help achieve its goals; 1) Gain
technical and clinical skills for translational studies on T-cell lymphomas, 2) Expand its knowledge related to
tumor progression and 3) Develop skills to become an independent scientist and write an R01 application to
the NCI.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.
刺激性淋巴瘤中的双重激酶 - 溴结构域抑制剂伏拉替氏菌的polo样酶1(PLK-1)和C-MYC抑制作用。
DOI:
10.18632/oncotarget.22967
发表时间:
2017-12-29
期刊:
Oncotarget
影响因子:
--
作者:
[Murga-Zamalloa C, Polk A, Hanel W, Chowdhury P, Brown N, Hristov AC, Bailey NG, Wang T, Phillips T, Devata S, Poonnen P, Gomez-Gelvez J, Inamdar KV, Wilcox RA]
通讯作者:
Wilcox RA
DOI:
10.1186/s13000-022-01237-0
发表时间:
2022-06-25
期刊:
Diagnostic pathology
影响因子:
2.6
作者:
[]
通讯作者:
Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T cell lymphomas
-
批准号:9751816
-
项目类别:
-
资助金额:$2.41万
-
财政年份:2017
-
负责人:Carlos A. Murga-Zamalloa
-
依托单位:
国内基金
海外基金
活性优化型先导编辑器精准替换WAS基因
突变热点区域治疗Wiskott-Aldrich综合
症小鼠模型研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:支胜尧
-
依托单位:
Wiskott-Aldrich综合征中的免疫缺陷:WASH蛋白在B细胞中的功能
-
批准号:32311530061
-
项目类别:国际(地区)合作与交流项目
-
资助金额:10万元
-
批准年份:2023
-
负责人:刘超红
-
依托单位: